Pancreatic cancer, of which pancreatic ductal adenocarcinoma is the most common type, is estimated to become the second leading cause of cancer-related death by 2030 in the United States ([@bib27]). A trend of increasing mortality rates for pancreatic cancer is also foreseen in Europe ([@bib22]; [@bib10]). The past decade has witnessed little therapeutic progress for this disease and obstacles to primary prevention persist on grounds of insufficient knowledge of the causative factors. In fact, only few risk factors of pancreatic cancer are well established, namely smoking, non-O blood group, obesity, diabetes mellitus, heavy alcohol drinking and chronic pancreatitis ([@bib21]). The identification of additional risk factors is a challenge due to the complex and multi-factorial aetiology of pancreatic cancer. Dietary factors, which could be potentially modifiable, have not been consistently linked to pancreatic cancer ([@bib1]).

Results from numerous epidemiological studies support the hypothesis that the Mediterranean diet (MD) is associated with a reduced cancer risk ([@bib9]; [@bib3]; [@bib32]), as for example concerns breast ([@bib7]), colorectal ([@bib2]) and gastric cancers ([@bib6]). The underlying mechanisms by which the MD may exert this cancer-preventive effect are based on the inhibition of inflammatory, mutagenic and proliferative pathways in the carcinogenic process, and have been attributed to the synergistic interplay of various nutritional components, for example, omega 6 and omega 3 fatty acids, fibre, antioxidants and polyphenols, provided by fruits, vegetables, legumes, olive oil and wine ([@bib11]). There is, however, limited and inconsistent data on the association between *a priori*-defined scores of adherence to the MD and pancreatic cancer risk, with an Italian case--control study of nearly 700 pancreatic cancer cases reporting a significant inverse association ([@bib5]), and two prospective studies, one conducted in the United States (*n*=1057 cases) and another one in Sweden (*n*=92 cases), reporting conflicting results ([@bib17]; [@bib36]). The null results from the US study could be attributed to an overall lower adherence to the MD compared with European populations, whereas the sample size of the Swedish study undermines the reliability of a true inverse association between the MD and pancreatic cancer risk. Studies on *a posteriori*-defined MD patterns and their association with pancreatic cancer risk have also reported contradictory results ([@bib23]; [@bib25]; [@bib15]; [@bib8]; [@bib4]). Therefore, it remains inconclusive whether an association between the MD and pancreatic cancer risk exists.

Despite the absence of a consistent pattern of association, a possible link between the MD and pancreatic cancer risk is supported by the fact that some dietary components of the MD have been associated individually with a reduced risk (e.g., fruits and vegetables) or increased risk (e.g., meat) of pancreatic cancer ([@bib40]; [@bib30]). Further support for this association comes from the well-known MD and diabetes mellitus association. A high adherence to the MD as compared with a low adherence leads to a decreasing risk of diabetes mellitus ([@bib16]; [@bib18]), which could subsequently reduce the risk of pancreatic cancer owing to the causal link between both diseases. Thus, the MD could have a potential role in reducing pancreatic cancer risk through diabetes as a mediating factor in this relationship, or by being a common preventive factor of both diabetes and pancreatic cancer.

Our aim was to prospectively investigate the association between adherence to an *a priori-*defined MD index and pancreatic cancer risk. To this end we used a large European study population, featuring a wide range of variability in adherence to the MD across a North--South gradient, which also included Mediterranean populations.

Materials and methods
=====================

Study population
----------------

European Prospective Investigation into Cancer and Nutrition is a multicenter prospective cohort study conducted in 23 centres in 10 European countries (Italy, France, Denmark, Germany, Greece, Spain, Norway, Sweden, UK and The Netherlands). Over half a million participants (30% men) were recruited in the 1990s from the general population, except in some centres where other target populations were approached: breast cancer screening participants in Florence (Italy) and Utrecht (The Netherlands), mostly blood donors in Italy and Spain, vegetarian and health-conscious volunteers in Oxford (UK), and female members of the health insurance scheme for state school employees in France. European Prospective Investigation into Cancer and Nutrition was approved by the Internal Review Board of the International Agency for Research on Cancer, as well as by local institutions of the participating centres. All participants provided written informed consent. Methods of recruitment have been described in detail elsewhere ([@bib29]; [@bib28]).

We excluded a total of 23 785 participants with prevalent cancer at baseline other than non-melanoma skin cancer, 4383 participants with missing or incomplete information on follow-up, 6253 participants with incomplete dietary or non-dietary data and 9600 participants with a ratio for energy intake *vs* energy expenditure in the top or bottom 1%. The final study sample comprised 477 309 participants (29.8% men).

Pancreatic cancer cases ascertainment
-------------------------------------

Record linkage with population-based cancer registries and national mortality registries was performed to identify incident cancer cases and to assess the vital status of the participants. Complete follow-up data were obtained between 2004 and 2008 depending on the EPIC centre. Active follow-up was carried out in Germany (up to 2008 for Potsdam and mid-2010 for Heidelberg), Greece (up to 2009) and France (up to 2006) by reviewing cancer, pathology and health insurance records of each participant, and also by directly contacting their next-of-kin. The mean duration of follow-up was 11.3 years.

Incident pancreatic cancer cases were defined as exocrine adenocarcinomas (International Classification of Diseases for Oncology, Third Edition (ICD-O-3), codes C25.0--C25.3, C25.7--C25.9). Endocrine tumours (*n*=40), secondary tumours (*n*=67) and tumours of uncertain, benign or metastatic behaviour (*n*=3) were all censored at the date of their diagnosis. We ended up with 865 pancreatic cancer cases, of which 608 cases (70.3%) were microscopically confirmed, based on histology of the primary tumour, histology of the metastasis, cytology or autopsy.

Assessment of diet and adherence to the MD
------------------------------------------

Participants were asked about their habitual diet over the previous year using country-specific validated dietary questionnaires ([@bib28]), namely: quantitative food frequency questionnaires in Germany, Greece, Northern Italy and the Netherlands, diet history questionnaires in Spain, France and Ragusa (Italy), and semi-quantitative food frequency questionnaires in Denmark, Naples (Italy), Norway, the UK (combined with a 7-day record) and Umeå (Sweden). In Malmö (Sweden), a quantitative food frequency questionnaire and a 7-day food record with menu book to estimate portion sizes were used. The EPIC nutrient database was used to estimate nutrient and total energy intake from the dietary questionnaires ([@bib33]).

The relative Mediterranean diet score (rMED), as previously applied in other EPIC studies ([@bib6], [@bib7]) and similar in concept to the original MD score ([@bib37]), was used to estimate level of conformity to the MD. It is an 18-point scale that incorporates nine selected components of the MD. Each component was calculated as a function of energy density (g per 1000 kcal per day), using the nutrient density model ([@bib39]), and then divided into country-specific tertiles of intakes (except for olive oil). For the six components presumed to fit the MD; fruits (including nuts and seeds), vegetables (excluding potatoes), legumes, fish (including seafood), olive oil and cereals (white and nonwhite), a score of 0--2 points was assigned to the first (0 points), second (1 point) and third (2 points) tertile of intake, respectively. The scoring scheme for olive oil consisted of assigning 0 points to non-consumers, 1 point for participants below the median of intake and 2 points for levels of intake equal or above this median. For the 2 components presumed not to fit MD, meat (including meat products) and dairy products, the scoring was reversed (first, second and third tertile: 2, 1 and 0 points, respectively). Because alcohol consumption has been potentially associated with pancreatic cancer ([@bib21]), the alcohol component (the ninth component) was removed from the score and the non-alcohol MD score (arMED) was used instead ([@bib7]). Thus, the range of the arMED score contained eight components and the point scale ranks from 0 to 16, whereby 0 represents the lowest adherence to the MD pattern and 16 the highest adherence. The arMED score was further classified into low (0--5 points), medium (6--9 points) or high (10--16 points) adherence levels based on the previously published cutoff points ([@bib7]).

Lifestyle data
--------------

Standardised questionnaires were used to collect lifestyle data at recruitment including self-reported diabetes status, history of smoking and alcohol consumption, physical activity and socio-economic status. Diagnosis of diabetes of about half of all self-reported cases was confirmed through linkage to diabetes mellitus registries, patient records or using other procedures ([@bib26]). Height and weight were measured in all EPIC centres except in Norway, France and in a subgroup of the Oxford cohort where these data were self-reported. Anthropometric measurements also included waist circumference, except in Norway, in Umeå and in Oxford where only self-reported data were collected ([@bib28]). Measurements were corrected for differences in clothing and self-reported data of the aforementioned centres were corrected using prediction equations based on a fraction of real measurements ([@bib13]).

Statistical analysis
--------------------

Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for adherence to the arMED score associated with pancreatic cancer risk. Regression models were stratified by age at recruitment in 1-year categories, sex and centre to control for between-centre differences in the dietary assessment methods used at recruitment and differences in follow-up procedures. Time at entry was age at recruitment, and time at exit was age at first pancreatic cancer diagnosis for cases and age at censoring for non-cases (death, loss to follow-up or end of the follow-up, whichever came first). The proportional hazard assumption was satisfied in all models as indicated by the plots of Schoenfeld residuals on functions of time ([@bib31]).

Adherence to the arMED was modelled as a categorical variable by dividing the score into low, medium and high levels of adherence. The low adherence category was considered as the referent group. The trend of association across levels of adherence was evaluated by using a linear variable of the medians of the score in each stratum.

Adherence to the arMED was also modelled on a continuous scale to estimate risks associated per increments of two units in the adherence. Restricted cubic splines functions in models of three and four knots on the distribution of the arMED score, to evaluate the shape of the dose--response relationship between the arMED and pancreatic cancer risk ([@bib14]), suggested a linear relationship.

Covariates considered *a priori* as factors known or suspected to be associated with pancreatic cancer risk and the MD were tested for confounding by comparing models with and without each variable. Those variables that changed estimates by more than 10% were retained in the regression model. Physical activity and educational level did not comply with these criteria. Risk estimates for models with waist circumference or body mass index (BMI) did not substantially differ. The association of adherence to the arMED score with pancreatic cancer risk was examined in crude models (stratified by age, sex and centre), and in multivariate models (additionally adjusted for energy intake, BMI, smoking status, alcohol intake and diabetes status).

The modifying effect of sex, BMI (normal, overweight and obese, according to WHO criteria), waist circumference (normal/moderate and large, according to [@bib24]), physical activity (active and non-active) to elucidate further the potential effect-measure modification of overweight and obesity, smoking status (never, former and current smoker), median age at recruitment (\<60 and ⩾60 years) and alcohol consumption (abstainers, moderate drinkers and drinkers, equivalent to 0 g/day, ⩽12 g/day or \>12 g/day alcohol use, respectively) was evaluated through stratified analyses and the likelihood ratio test statistic in regression models with and without multiplicative interaction terms between these variables and the arMED score. In addition, we considered the influence of smoking duration and intensity on the arMED and pancreatic cancer risk association in current and former smokers. Heterogeneity by country and region (Southern, Central and Northern Europe) was also assessed by introducing an interaction term between countries/regions and the arMED score in the model.

The possible mediating effect of diabetes mellitus on this association was further evaluated in two different scenarios using mediation analysis ([@bib35]): (i) a direct effect of the arMED score on pancreatic cancer risk; and (ii) an indirect effect with diabetes mellitus as an intermediate in the causal pathway. A logistic regression model of the arMED score on diabetes status at baseline, followed by a hazard model to the onset of pancreatic cancer including arMED and the same covariates as well as the mediator variable (diabetes status) were fitted to estimate the average direct and the average causal mediation effect of diabetes.

Sensitivity analyses were performed by the exclusion of cases diagnosed within the first 2 years of follow-up (88 cases) to evaluate the influence of early effects of subclinical disease on the associations as well as those occurred within the first 5 years of follow-up (258 cases) to account for another time point of disease progression. We also excluded (i.e., censored) non-microscopically confirmed cases (257 cases) to minimise possible misclassification of tumours. Analyses were further restricted to 523 confirmed cases belonging to the pancreatic ductal adenocarcinoma histological subtype. Hazard ratios of pancreatic cancer associated with adherence to the arMED score were compared with the score including alcohol as an additional component, that is, the original rMED score ([@bib6]). Alcohol was scored dichotomously assigning two for moderate consumption (sex-specific cutoff points: 5--25 g per day for women and 10--50 g per day for men) and 0 for intakes outside this range. Other sensitivity analyses included the comparison of HRs estimated using cohort-wide tertiles, the Mediterranean diet scale (MDS; [@bib37]) and the Mediterranean dietary pattern MDP scores ([@bib34]). Analyses excluding misreporters of energy intake, as defined by Goldberg (under-repoters if ratio of energy intake:basal metabolic rate -EI:BMR \<1.14 and over-reporters if EI:BMR \>2.1), were also conducted ([@bib12]). In addition, each dietary component of the MD score was subtracted one at a time from the arMED score to investigate whether the removed component changed the risk estimates with respect to the regression models of the complete arMED score.

Statistical software used for the data analysis were Stata 12.0 (College Station, TX, USA: Stata Corp LP, 2005) and R 3.2.1. Statistical significance was based on two-sided *P* values \<0.05.

Results
=======

The arMED score ranged between 4 and 11.3 points (mean score: 7.81±2.63). Mean overall adherence to the arMED score was higher in southern European countries than in northern European countries, except in the UK (possibly driven by the vegetarian and health-conscious participants of the Oxford subcohort) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). According to the participants\' demographic and lifestyle characteristics, higher levels of adherence to the arMED score were more frequent among those who were younger, less educated, non-smokers, physically inactive or obese. Participants with self-reported diabetes mellitus at baseline also showed a higher adherence level to this dietary pattern probably as a result of adopting healthier dietary habits to manage their disease. Intakes of nutrient antioxidants, fibre, plant-based food and olive oil were higher in the high adherence group, while that of dairy products and meats was lowest ([Table 1](#tbl1){ref-type="table"}).

[Table 2](#tbl2){ref-type="table"} shows HR estimates of adherence to the arMED score associated with pancreatic cancer risk, overall and by subgroups. Compared with a low level of adherence to the arMED score, a higher adherence was not associated with risk of pancreatic cancer, either in the minimally adjusted (HR=0.88; 95% CI: 0.69--1.12; *p-trend*=0.24), or multivariate-adjusted models (HR=0.99; 95% CI: 0.77--1.26; *p-*trend=0.95). HRs associated to increments of two units in the adherence to the arMED score did also not reach statistical significance (HR=1.00; 95% CI: 0.94--1.06).

No indication for effect modification by BMI, age, smoking status, sex, physical activity, alcohol status and abdominal obesity was apparent (*P-*value for interaction=0.43, 0.59, 0.56, 0.90, 0.46, 0.20 and 0.76, respectively). There was also no evidence for interaction by diabetes status (*P*-value=0.11). Hazard ratios for pancreatic cancer per two units increment in arMED in non-diabetics tended to be inversely associated with pancreatic cancer risk in crude models (HR=0.97; 95% CI: 0.94--1.00), but not after adjusting for smoking in the multivariate-adjusted model (HR=0.98; 95% CI: 0.91--1.04). No such inverse pattern of association was observed in the subset of diabetics, although a relatively small number of pancreatic cancer cases (*n*=55) were available for this analysis (data not shown). Results of the mediation analysis also did not support a mediating effect of diabetes on this association (average causal mediation effect *P*-value=0.90, average direct effect *P*-value=0.02).

Stratified analyses by country or European region did not reveal statistically significant heterogeneity between strata for the association between adherence to the arMED score with pancreatic cancer risk (*P*-value=0.62 and 0.11, respectively). A borderline inverse association in the southern European cohort was observed, yet without reaching statistical significance (HR per two unit increment in arMED=0.88; 95% CI: 0.76--1.03, *P*-value=0.07).

Results of the sensitivity analyses are shown in [Table 3](#tbl3){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Hazard ratios remained virtually the same in analyses restricted to microscopically confirmed cases or to participants with a follow-up longer than 2 or 5 years. No differences in the associations were further observed for pancreatic ductal adenocarcinoma tumours. The distribution of participants by the arMED score either defined as country-specific or cohort-wide tertiles was similar (23.1%, 46.7%, 29.4% and 24.2%, 45.3%, 30.5%, respectively) and HR estimates did not appreciably change when cohort-wide tertiles of the arMED score were used as the exposure of interest variable. We did also not observe any variations in risk estimates when considering adherence to the rMED score, that is, the score including alcohol, instead. The same was true for the other MD scores (MDS and MDP), with or without the contribution of alcohol to the scores. Estimates of HRs in the study population of valid reporters of energy intake did also not reach the level of statistical significance (HR per two unit increments in arMED=0.95; 95% CI: 0.88--1.03). Furthermore, no differences in risk estimates were seen after removing each arMED component of the score ([Table 3](#tbl3){ref-type="table"}). In addition, none of these components was individually associated with pancreatic cancer risk in multivariate-adjusted models controlling for the remaining components (data not shown).

Discussion
==========

Risk of pancreatic cancer was not associated with adherence to a non-alcohol defined MD score (arMED) in this large European prospective cohort study, nor was there any evidence of a significant association between the arMED score and pancreatic cancer risk in stratified analyses by diabetes, smoking, BMI or European region.

Few studies have examined the association between adherence to the MD and pancreatic cancer risk. The National Institutes of Health-AARP Diet and Health Study prospectively evaluated this association in a diabetes-free study population including 1057 pancreatic cancer cases ([@bib17]). In this study, adherence to the MD was considered as part of a healthy lifestyle score, which also included tobacco and alcohol consumption, BMI and physical activity. The MD score was derived from the MDS ([@bib37]), but was further adapted by removing the alcohol component. The risk of pancreatic cancer was significantly lower in participants who scored highest compared with those in the group of lowest compliance with the lifestyle score (RR=0.42; 95% CI: 0.26--0.66). The independent effect of the MD score on pancreatic cancer risk was also evaluated in this study, but a non-statistically significant 8% (95% CI 0.81--1.05) reduced pancreatic cancer risk was seen when a high *vs* a low non-alcohol MD adherence was compared, indicating that a healthy dietary pattern, such as the MD, may not have the capacity on its own to reduce risk of pancreatic cancer. Interestingly, non-smoking (never or former smokers who quit smoking for 10 or more years) and normal weight (BMI \<25 kg m^2^) were the only two features of the lifestyle score independently associated with a decreased pancreatic cancer risk. Non-smoking yielded the greatest risk reduction within the score (RR=non-smokers *vs* smokers=0.59; 95% CI: 0.51--0.67). Therefore, the pancreatic cancer risk-reducing effect of this lifestyle score could be entirely attributed to the smoking component. In support of this argument, a cross-comparison of smoking status and levels of adherence to the arMED score in our study revealed that non-smokers, defined likewise as never or long-term former smokers (⩾10 years), with a high adherence to the arMED score as compared with current smokers or early former smokers with a low adherence to the arMED score had a 42% (95% CI: 0.43--0.78) lower risk of pancreatic cancer.

Another prospective study addressing the association between adherence to the MD (defined as the MDS, with some modifications) and pancreatic cancer mortality reported a 28% reduction in mortality (though, statistically significant only in men: 95% CI: 0.68--0.99) for high *vs* low adherence to the MD score ([@bib36]). This study included only 92 pancreatic cancer cases, which were ascertained in Sweden among the 77 151 participants of the Västerbotten Intervention Program study. Residual confounding and selection bias (subjects with higher mortality risk were excluded) prevent direct comparison of their results with those obtained in our study. The only study reporting a significant association between the MD (the MDS) and pancreatic cancer is an Italian case--control study that included 688 cases and 2204 hospital-based controls. In this study, risk of pancreatic cancer decreased by 15% (95% CI: 0.80--0.91) per one unit increment in the adherence to the MD ([@bib5], [@bib4]). This association was consistent across strata of age, BMI, alcohol and smoking status, and was stronger in non-diabetics (OR=0.84) as compared with diabetics (OR=0.99; *P*-value for interaction: 0.01). In our study, high *vs* low adherence to the arMED score also pointed to a stronger, though non-statistically significant, inverse association between the MD and pancreatic cancer risk in non-diabetics (HR=0.91; 95% CI: 0.70--1.19). We could not examine the association in diabetics because only 55 of them developed pancreatic cancer during follow-up, but we did not observe any evidence for effect modification by diabetes status. The other prospective studies did not assess how MD is associated with pancreatic cancer risk in diabetics as compared with non-diabetics. Although the number of diabetics with pancreatic cancer was limited in number in our study population, our results suggest that diabetes status does not mediate any possible association between the MD and pancreatic cancer risk.

Finally, a recently published meta-analysis on the adherence to the MD and cancer incidence and mortality concluded for pancreatic cancer that a high adherence to this dietary pattern leads to a statistically non-significant reduced risk (RR=0.64; 95% CI: 0.38--1.08) when compared with a low adherence ([@bib32]). However, this reported risk estimate was not derived from all available published studies on this association; only estimates of the Italian and Swedish studies were pooled.

All of these earlier studies exploring the association between the MD and pancreatic cancer risk are prone to misclassification of the outcome (data for histologically confirmed cases were not provided), and some of them did not account for implausible reporting of dietary intake on the basis of estimated energy requirements to rule out exposure misclassification. Selection bias, although less likely present in cohort studies, might be another issue. Also, MD patterns in American and Nordic populations might not adequately reflect the traditional MD pattern. In our study, the association was, indeed, to some extent stronger in southern European countries, though it still did not reach statistical significance. Thus, our results seem to indicate that adherence to the MD does not reduce pancreatic cancer risk.

Similarly, two prospective studies assessing *a posteriori-*defined MD-like dietary patterns reported no association with pancreatic cancer risk ([@bib23]; [@bib15]). Also, neither single dietary components of the MD nor the combination of them in the arMED score appeared to be linked to pancreatic cancer risk in our study. In addition, we rendered similar risk estimates after considering the traditional rMED score that includes the alcohol component ([@bib6]). Overall, evidence supporting a role of dietary factors commonly supplied by the MD (antioxidant-rich foods, such as fruits and vegetables, and limited intake of red meat) for the prevention of this disease is still sparse ([@bib38]; [@bib1]; [@bib19]; [@bib20]; [@bib30]).

Several limitations of this study should be considered. Our results rely on dietary data measured at a single time point, which would not reflect longitudinal changes in dietary intake. Residual confounding might be present as we were unable to control for all known risk factors of pancreatic cancer, such as family history of pancreatic cancer, or for other putative factors potentially associated with pancreatic cancer risk. Confounding by smoking might be also an issue, despite the fact that additionally controlling for smoking duration and intensity did not substantially affect our results. Diabetes mellitus status could have biased our results due to misclassification, but neither self-reported nor validated data on type 2 diabetes mellitus status at baseline made a substantial difference.

Strengths of our study are its prospective nature, as well as the large sample size and long follow-up, which enabled us to conduct stratified analysis by potential effect modifiers with sufficient statistical power. Also, we were able to minimise bias due to misclassification of the outcome after restricting the study population to microscopically confirmed cases, and could confirm absence of any influence of pre-diagnostic disease on the association. Moreover, our results remained unchanged at different follow-up time points. We excluded misreporters of energy intake to ensure that reporting bias did not influence our results. However, as in any other diet-cancer association study, dietary measurement error cannot be dismissed. Our results also rely on a MD score that has been widely used in diet-cancer risk-association studies, in which the utility of the MD for the primary prevention of various cancer sites was demonstrated ([@bib6], [@bib7]; [@bib2]). Moreover, our study addresses the MD-pancreatic cancer risk association, for the first time, in a large European population that includes countries from the Mediterranean regions, accounting for a wide range of adherence to the MD pattern.

In conclusion, results of our study, conducted within the prospective EPIC cohort, suggest that adherence to the MD is not associated with the development of pancreatic cancer.
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###### Baseline characteristics of the EPIC cohort (*n*=477 309) according to adherence to the arMED score

                                                                            **arMED score in men**   **arMED score in women**                                                          
  ------------------------------------------------------------------------ ------------------------ -------------------------- ------------------- ----------------- ----------------- -----------------
  Adherence arMED (mean±s.d.)                                                    3.85 (1.14)               7.35 (1.11)            11.37 (1.32)        4.14 (1.01)       7.54 (1.10)      11.28 (1.28)
  Age, years (mean±s.d.)                                                           52.3±9.9                 52.6±10.0               51.2±10.6          51.4±9.7          51.2±9.3          49.8±10.6
  Education ⩾secondary school, *n* (%)                                          32 690 (66.1)             39 000 (66.6)           18 781 (54.9)      41 981 (69.3)    119 520 (71.0)     65 328 (61.6)
  Weight, kg (mean±s.d.)                                                          82.0±12.4                 80.7±11.8               79.4±11.6          67.2±12.3         65.5±11.5         65.0±11.4
  BMI, kg m^2^ (mean±s.d.)                                                         26.3±3.6                  26.4±3.6               27.0±3.8           25.1±4.4          24.7±4.2          25.2±4.6
  Obese (⩾30 kg m^2^), *n* (%)                                                   6926 (14.0)               8278 (14.1)             6596 (19.3)        7780 (12.9)      18 547 (11.0)     15 912 (15.0)
  Waist circumference, cm (mean±s.d.)                                             95.0±10.4                 94.0±10.0               95.2±10.2          81.0±11.4         79.6±11.0         80.3±11.9
  ⩾102 cm in men or ⩾88 cm in women, *n* (%)                                     9832 (19.9)              11 232 (19.2)            8601 (25.1)       11 022 (18.2)     23 151 (13.8)     21 266 (20.1)
  Physical activity \>moderate active, *n* (%)                                  24 329 (49.2)             28 274 (48.3)           16 315 (47.7)      24 169 (39.9)     59 685 (35.4)     34 380 (32.4)
  Current smoker, *n* (%)                                                       16 269 (32.9)             15 779 (26.9)            9758 (28.5)       17 069 (28.2)     32 311 (19.2)     15 903 (15.0)
  Alcohol intake, median g (IQR)                                               12.1 (4.1--29.2)          13.8 (4.8--30.7)       13.04 (3.4--29.8)   3.8 (0.8--11.4)   3.9 (0.8--11.6)   2.8 (0.4--10.2)
  Heavy intake (⩾96 g per day in men or ⩾60 g per day in women), *n* (%)          3623 (7.3)                3853 (6.6)             1887 (5.5)          637 (1.1)        1178 (0.7)         361 (0.3)
  **Dietary intake**                                                                                                                                                                   
  Total energy intake, kcal (mean±s.d.)                                            2470±665                  2391±657               2356±660           1956±533          1929±543          1921±539
  Carbohydrate, g (mean±s.d.)                                                     261.4±80.6                259.5±82.4             250.7±79.9         211.0±65.6        213.8±66.6        219.7±69.1
  Fat, g (mean±s.d.)                                                              98.7±33.0                 91.0±31.4               91.8±33.2          79.7±26.7         75.7±26.9         74.4±26.8
  Saturated fat, g (mean±s.d.)                                                    41.2±14.8                 34.6±13.0               28.2±11.3          33.9±12.4         30.1±11.8         25.7±10.6
  Vitamin C, mg (mean±s.d.)                                                       96.5±52.1                 121.9±67.3             158.5±88.6         100.7±54.7        128.9±65.5        154.5±73.8
  Vitamin E, mg (mean±s.d.)                                                        11.7±6.0                  13.3±6.4               14.7±6.7           10.8±5.2          11.8±5.4          12.6±5.4
  Beta-carotene, μg (mean±s.d.)                                                 2327.3±1980.6             3080.5±2589.8           4062.6±3284.8      2917.0±2086.0     3735.4±2668.0     4660.2±3591.7
  Folate, μg (mean±s.d.)                                                          285.7±90.4               313.6±109.1             376.5±139.9        254.2±87.2        293.2±109.9       348.6±37.6
  Fibre, g (mean±s.d.)                                                             21.5±7.3                  24.5±8.0               28.0±8.9           18.5±5.9          21.6±6.5          25.1±8.0
  Meat and meat products, g (mean±s.d.)                                           148.6±69.0                120.9±65.4              96.6±65.7         109.0±49.8         92.0±50.6         67.8±48.3
  Dairy products, g (mean±s.d.)                                                  450.8±321.0               311.0±225.3             214.9±164.6        434.4±263.4       329.9±211.2       245.7±172.0
  Fruit, nuts and vegetables, g (mean±s.d.)                                      234.8±131.0               387.6±218.9             693.4±323.5        278.3±151.4       431.4±223.8       637.4±282.7
  Cereals, g (mean±s.d.)                                                          214.0±95.6               269.7±135.6             295.0±135.8        162.8±71.0        197.5±93.5        235.5±109.7
  Legumes, g (mean±s.d.)                                                           4.4±10.6                 14.3±26.5               35.9±36.6           4.2±9.6          10.3±17.2         25.3±25.8
  Fish, g (mean±s.d.)                                                             27.5±25.6                 36.5± 32.0              48.6±43.9          24.6±28.1         38.7±37.5         43.4±37.4
  Olive oil, g (mean±s.d.)                                                         0.4±2.3                   7.0±14.0               26.1±23.5           0.5±2.4           3.6±9.2          12.6±17.1
  Diabetes, yes (self-reported), n (%)                                            1309 (2.7)                2219 (3.8)             1572 (4.6)         1090 (1.8)        3440 (2.0)        2902 (2.7)

All dietary intakes are estimated from the food frequency questionnaire and not energy-adjusted.

Missing data on educational level for 1260 men and 4964 women; physical activity for 3075 men and 38 956 women; waist circumference for 12 043 men and 94 998 women; smoking status for 1959 men and 7774 women; diabetes status at recruitment for 3096 men and 13 745 women.

###### Hazard ratios (95% confidence intervals) of pancreatic cancer by country-specific levels of adherence to the arMED score in the EPIC cohort (*n*=477 309)

                                                                       **arMED score**   **Per two unit increment in arMED score**                                                                              
  ------------------------------------------------------------------- ----------------- ------------------------------------------- ------------------------------------- ------------------------------------- -------------------
  **All (*n*=865 cases)**                                                                                                                                                                                       
  Cases/person-years                                                    277/1 245 196                  402/2 483 735                            186/1 534 067                                                             
  Crude HR (95% CI)                                                         1.00                     0.94 (0.80--1.11)                        0.88 (0.69--1.12)                           0.24                   0.98 (0.95--1.01)
  Multivariate HR (95% CI)                                                  1.00                     1.01 (0.85--1.19)                        0.99 (0.77--1.26)                           0.95                   1.00 (0.94--1.06)
  **Men (*n*=396 cases)**                                                                                                                                                  ***P*-value for interaction: 0.90**  
  Cases/person-years                                                     165/565 143                    160/649 987                              71/376 379                                                               
  Crude HR (95% CI)                                                         1.00                     0.92 (0.73--1.16)                        0.88 (0.59--1.30)                           0.45                   0.97 (0.88--1.06)
  Multivariate HR (95% CI)                                                  1.00                     0.99 (0.78--1.25)                        1.00 (0.68--1.49)                           0.99                   1.01 (0.92--1.11)
  **Women (*n*=469 cases)**                                                                                                                                                                                     
  Cases/person-years                                                     112/680 053                   242/1 833 748                            115/1 157 688                                                             
  Crude HR (95% CI)                                                         1.00                     0.96 (0.76--1.21)                        0.89 (0.65--1.22)                           0.46                   0.96 (0.88--1.04)
  Multivariate HR (95% CI)                                                  1.00                     1.03 (0.82--1.31)                        0.99 (0.72--1.37)                           0.98                   0.99 (0.91--1.08)
  **Age \<60 years (*n*=486 cases)**                                                                                                                                       ***P*-value for interaction: 0.59**  
  Cases/person-years                                                     168/965 742                   225/1 970 708                            93/1 249 488                                                              
  Crude HR (95% CI)                                                         1.00                     0.88 (0.71--1.09)                        0.71 (0.51--0.98)                           0.04                   0.94 (0.87--1.03)
  Multivariate HR (95% CI)                                                  1.00                     0.95 (0.76--1.18)                        0.80 (0.58--1.12)                           0.23                   0.98 (0.90--1.07)
  **Age ⩾60 years (*n*=379 cases)**                                                                                                                                                                             
  Cases/person-years                                                     109/279 454                    177/513 027                              93/284 579                                                               
  Crude HR (95% CI)                                                         1.00                     1.03 (0.80--1.33)                        1.16 (0.80--1.67)                           0.46                   0.99 (0.89--1.08)
  Multivariate HR (95% CI)                                                  1.00                     1.10 (0.85--1.41)                        1.30 (0.89--1.87)                           0.18                   1.02 (0.92--1.12)
  **Never smoker (*n*=336 cases)**                                                                                                   ***P*-value for interaction: 0.56**                                        
  Cases/person-years                                                     81/518 518                    169/1 229 294                             86/847 954                                                               
  Crude HR (95% CI)                                                         1.00                     1.02 (0.77--1.36)                        0.91 (0.62--1.34)                           0.65                   0.98 (0.88--1.08)
  Multivariate HR (95% CI)                                                  1.00                     1.03 (0.77--1.37)                        0.92 (0.63--1.37)                           0.71                   0.98 (0.89--1.09)
  **Former smoker (*n*=239 cases)**                                                                                                                                                                             
  Cases/person-years                                                     68/340 265                     115/681 518                              56/376 769                                                               
  Crude HR (95% CI)                                                         1.00                     1.13 (0.83--1.55)                        1.35 (0.87--2.12)                           0.19                   1.03 (0.92--1.16)
  Multivariate HR (95% CI)                                                  1.00                     1.15 (0.83--1.57)                        1.42 (0.91--2.22)                           0.13                   1.05 (0.93--1.18)
  **Smoker (*n*=247 cases)**                                                                                                                                                                                    
  Cases/person-years                                                     126/371 157                    109/519 272                              40/278 996                                                               
  Crude HR (95% CI)                                                         1.00                     0.84 (0.64--1.12)                        0.66 (0.40--1.08)                           0.09                   0.94 (0.84--1.05)
  Multivariate HR (95% CI)                                                  1.00                     0.86 (0.65--1.14)                        0.67 (0.41--1.11)                           0.11                   0.95 (0.85--1.06)
  **Non-diabetics (*n*=776 cases)**                                                                                                  ***P*-value for interaction: 0.11**                                        
  Cases/person-years                                                    259/1 174 297                  355/2 321 163                            162/1 448 174                                                             
  Crude HR (95% CI)                                                         1.00                     0.89 (0.75--1.05)                        0.81 (0.63--1.05)                           0.09                   0.97 (0.94--1.00)
  Multivariate HR (95% CI)                                                  1.00                     0.95 (0.80--1.13)                        0.91 (0.70--1.19)                           0.48                   0.98 (0.91--1.04)
  **Obese (*n*=144 cases)**[a](#t2-fn3){ref-type="fn"}                                                                               ***P*-value for interaction: 0.43**                                        
  Cases/person-years                                                     45/161 481                     65/290 699                               34/245 613                                                               
  Crude HR (95% CI)                                                         1.00                     1.03 (0.67--1.57)                        0.53 (0.28--1.03)                           0.11                   0.90 (0.77--1.05)
  Multivariate HR (95% CI)                                                  1.00                     1.06 (0.69--1.64)                        0.56 (0.29--1.08)                           0.14                   0.91 (0.78--1.08)
  **Overweight (*n*=363 cases)**[b](#t2-fn4){ref-type="fn"}                                                                                                                                                     
  Cases/person-years                                                     115/478 180                   164/ 837 232                              84/527 638                                                               
  Crude HR (95% CI)                                                         1.00                     0.99 (0.77--1.28)                        1.05 (0.72--1.53)                           0.83                   0.99 (0.90--1.09)
  Multivariate HR (95% CI)                                                  1.00                     1.08 (0.83--1.40)                        1.19 (0.81--1.73)                           0.38                   1.03 (0.94--1.14)
  **Normal weight (*n*=358 cases)**[b](#t2-fn4){ref-type="fn"}                                                                                                                                                  
  Cases/person-years                                                     117/605 535                   173/1 355 804                             68/760 817                                                               
  Crude HR (95% CI)                                                         1.00                     0.90 (0.70--1.16)                        0.92 (0.64--1.32)                           0.56                   0.98 (0.94--1.03)
  Multivariate HR (95% CI)                                                  1.00                     0.97 (0.75--1.25)                        1.02 (0.70--1.47)                           0.97                   1.00 (0.90--1.10)
  **Physically active (*n*=173 cases)**                                                                                              ***P*-value for interaction: 0.46**                                        
  Cases/person-years                                                     117/555 538                    157/980 914                              49/560 756                                                               
  Crude HR (95% CI)                                                         1.00                     1.04 (0.80--1.34)                        0.81 (0.53--1.24)                           0.53                   0.98 (0.89--1.09)
  Multivariate HR (95% CI)                                                  1.00                     1.09 (0.84--1.41)                        0.89 (0.58--1.36)                           0.86                   1.01 (0.91--1.12)
  **Non-physically active (*n*=505 cases)**                                                                                                                                                                     
  Cases/person-years                                                     151/596 061                   220/1 231 169                             134/908 833                                                              
  Crude HR (95% CI)                                                         1.00                     0.88 (0.70--1.10)                        0.92 (0.67--1.26)                           0.58                   0.97 (0.89--1.05)
  Multivariate HR (95% CI)                                                  1.00                     0.94 (0.75--1.18)                        1.04 (0.75--1.43)                           0.89                   1.00 (0.92--1.09)
  **Non-drinkers (*n*=109 cases)**[a](#t2-fn3){ref-type="fn"}                                                                        ***P*-value for interaction: 0.20**                                        
  Cases/person-years                                                     34/127 697                     45/300 841                               30/277 857                                                               
  Crude HR (95% CI)                                                         1.00                     0.78 (0.48--1.27)                        0.68 (0.33--1.39)                           0.26                   0.92 (0.77--1.11)
  Multivariate HR (95% CI)                                                  1.00                     0.84 (0.51--1.39)                        0.78 (0.38--1.63)                           0.49                   0.97 (0.80--1.16)
  **Moderate drinkers (*n*=437 cases)**[a](#t2-fn3){ref-type="fn"}                                                                                                                                              
  Cases/person-years                                                     120/697 692                   123/1 422 417                             104/836 632                                                              
  Crude HR (95% CI)                                                         1.00                     1.08 (0.85--1.37)                        1.13 (0.81--1.58)                           0.46                   1.03 (0.94--1.12)
  Multivariate HR (95% CI)                                                  1.00                     1.12 (0.88--1.43)                        1.20 (0.86--1.69)                           0.27                   1.05 (0.96--1.15)
  **Drinkers (*n*=319 cases)**[a](#t2-fn3){ref-type="fn"}                                                                                                                                                       
  Cases/person-years                                                     123/419 807                    144/760 477                              52/419 578                                                               
  Crude HR (95% CI)                                                         1.00                     0.85 (0.66--1.11)                        0.73 (0.48--1.11)                           0.12                   0.90 (0.81--1.00)
  Multivariate HR (95% CI)                                                  1.00                     0.95 (0.73--1.24)                        0.84 (0.55--1.29)                           0.45                   0.95 (0.85--1.05)
  **Abdominal obese (*n*=237 cases)**[b](#t2-fn4){ref-type="fn"}                                                                     ***P*-value for interaction: 0.76**                                        
  Cases/person-years                                                     69/226 129                     106/373 247                              62/328 889                                                               
  Crude HR (95% CI)                                                         1.00                     1.20 (0.87--1.67)                        0.87 (0.53--1.44)                           0.84                   0.96 (0.85--1.09)
  Multivariate HR (95% CI)                                                  1.00                     1.29 (0.92--1.80)                        0.98 (0.59--1.62)                           0.80                   0.99 (0.87--1.12)
  **Normal/moderate WC (*n*=522 cases)**[b](#t2-fn4){ref-type="fn"}                                                                                                                                             
  Cases/person-years                                                     172/727 819                   247/1 465 094                             103/990 891                                                              
  Crude HR (95% CI)                                                         1.00                     0.90 (0.74--1.11)                        0.82 (0.60--1.12)                           0.20                   0.97 (0.89--1.05)
  Multivariate HR (95% CI)                                                  1.00                     0.97 (0.79--1.20)                        0.94 (0.68--1.28)                           0.68                   1.01 (0.93--1.09)
  **Southern Europe (*n*=163 cases)**[c](#t2-fn5){ref-type="fn"}                                                                     ***P*-value for interaction: 0.11**                                        
  Cases/person-years                                                      2/22 293                      67/434 389                               94/774 018                                                               
  Crude HR (95% CI)                                                         1.00                     1.57 (0.38--6.48)                        1.07 (0.26--4.45)                           0.06                   0.86 (0.74--1.00)
  Multivariate HR (95% CI)                                                  1.00                     1.60 (0.39--6.61)                        1.16 (0.28--4.81)                           0.12                   0.88 (0.76--1.03)
  **Central Europe (*n*=341 cases)**[c](#t2-fn5){ref-type="fn"}                                                                                                                                                 
  Cases/person-years                                                     93/577 960                    179/1 255 044                             69/616 619                                                               
  Crude HR (95% CI)                                                         1.00                     1.06 (0.82--1.38)                        1.25 (0.87--1.80)                           0.25                   1.04 (0.94--1.15)
  Multivariate HR (95% CI)                                                  1.00                     1.10 (0.85--1.44)                        1.33 (0.92--1.93)                           0.14                   1.06 (0.96--1.17)
  **Northern Europe (*n*=361 cases)**[c](#t2-fn5){ref-type="fn"}                                                                                                                                                
  Cases/person-years                                                     182/644 942                    156/794 302                              23/143 430                                                               
  Crude HR (95% CI)                                                         1.00                     0.83 (0.67--1.04)                        0.79 (0.50--1.23)                           0.10                   0.94 (0.85--1.03)
  Multivariate HR (95% CI)                                                  1.00                     0.92 (0.73--1.15)                        0.93 (0.59--1.47)                           0.52                   0.99 (0.90--1.09)

Crude HRs---stratified by age (1-year categories), sex and centre.

Multivariate HRs---adjusted for total energy intake (continuous), body mass index (continuous), smoking status and intensity (never; current, 1--15 cigarettes per day; current, 16--25 cigarettes per day; current, 26+ cigarettes per day; former, quit ⩽10 years; former, quit 11--20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), alcohol intake (non-drinkers, drinkers of 0--6 g per day, \>6--12 g per day, \>12--24 g per day, \>24--60 g per day, women drinkers of: \>60 g per day, men drinkers of: \>60--96 g per day, \>96 g per day), diabetes (verified, not verified but self-reported, not diabetes, missing), and stratified by age (1-year categories), sex and centre. Abdominal obesity, according to NCEP/ATPIII criteria, was defined as waist circumference ⩾102 cm in men or ⩾88 cm in women, and normal and moderate waist circumference as \<120 cm or \<88 cm in men and women, respectively. Multivariate HRs additionally controlling for BMI retrieved similar estimates.

Non-drinkers: 0 drinks per day (0 g per day alcohol); moderate drinkers: no more than 1 drink/d (\>=12 g per day alcohol); drinkers: more than 1 drink per day (\>12 g per day alcohol).

Obese, overweight and normal weight was defined according to WHO criteria, as ⩾30 kg m^2^, 25--30 kg m^2^ and ⩽25 kg m^2^, respectively.

Southern Europe: Spain, Italy and Greece; Central Europe: France, Germany, UK and The Netherlands; Northern Europe: Sweden, Denmark and Norway.

###### Hazard ratios and 95% CIs of pancreatic cancer associated with the arMED score in the EPIC cohort (*n*=477 309) after removing score components one at a time

                                                             **HR**[a](#t3-fn3){ref-type="fn"} **(95% CI)**                                                 
  ------------------------------------------- ------------- ------------------------------------------------ ------------------- ------------------- ------ -------------------
  Vegetables[b](#t3-fn4){ref-type="fn"}       106.7±74.3                          1.00                        0.98 (0.84--1.15)   0.94 (0.71--1.26)   0.72   0.99 (0.92--1.06)
  Fruits[b](#t3-fn4){ref-type="fn"}           120.2±90.5                          1.00                        1.03 (0.88--1.21)   1.02 (0.77--1.35)   0.79   1.00 (0.93--1.07)
  Legumes[b](#t3-fn4){ref-type="fn"}          7.1±11.0                            1.00                        1.05 (0.90--1.23)   1.02 (0.78--1.34)   0.69   1.00 (0.94--1.07)
  Fish[b](#t3-fn4){ref-type="fn"}             18.9±19.1                           1.00                        1.04 (0.88--1.23)   1.04 (0.78--1.37)   0.69   0.99 (0.96--1.03)
  Cereals[b](#t3-fn4){ref-type="fn"}          161.5±110.8                         1.00                        0.98 (0.83--1.15)   0.89 (0.67--1.18)   0.50   1.00 (0.94--1.08)
  Olive oil[b](#t3-fn4){ref-type="fn"}        3.3±6.7                             1.00                        0.91 (0.78--1.06)   1.00 (0.77--1.30)   0.62   0.99 (0.93--1.06)
  Meat[b](#t3-fn4){ref-type="fn"}             47.4±25.0                           1.00                        1.02 (0.86--1.20)   1.08 (0.82--1.42)   0.64   1.00 (0.94--1.08)
  Diary products[b](#t3-fn4){ref-type="fn"}   161.5±110.8                         1.00                        1.04 (0.88--1.23)   1.09 (0.83--1.44)   0.51   1.01 (0.94--1.08)
  Alcohol[c](#t3-fn5){ref-type="fn"}          0.4±0.5                             1.00                        1.01 (0.85--1.19)   0.99 (0.77--1.26)   0.95   1.00 (0.94--1.06)

Intakes adjusted by energy intake (1000 kcal).

Multivariate HRs did not include alcohol intake.

Multivariate HRs---adjusted for total energy intake (continuous), body mass index (continuous), smoking status and intensity (never; current, 1--15 cigarettes per day; current, 16--25 cigarettes per day; current, 26+ cigarettes per day; former, quit ⩽10 years; former, quit 11--20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), alcohol intake (non-drinkers, drinkers of 0--6 g per day, \>6--12 g per day, \>12--24 g per day, \>24--60 g per day, women drinkers of: \>60 g per day, men drinkers of: \>60--96 g per day, \>96 g per day), diabetes (verified, not verified but self-reported, not diabetes, missing) and stratified by age (1-year categories), sex and centre.

Referers to the arMED score. Adherence score is based on 14 points.

Refers to the rMED score. Adherence score is based on 16 points.
